In order to detect diagnostic clues to identify patients with chronic immunethrombocytopenia which is likely to develop systemic lupus erythematosus (SLE), a retrospective study was conducted. Of 39 patients with chronic immune thrombocytopenia, 4 fulfilled the diagnostic criteria being between 4.5 and 14 years after the initial diagnosis of "idiopathic" thrombocytopenic purpura. The remaining 35 patients were found to be idiopathic thrombocytopenic purpura (ITP) after at least a 5-year follow-up. It was noted that in patients with SLE whohad thrombocytopenia at presentation, only 4 or 5 findings of diagnostic criteria were observed. Of particular interest, all patients who developed SLE were positive for anti-SS-A antibody, in contrast none of the patients with ITP had this antibody. Furthermore, despite the few clinical manifestations, we noted lupus peritonitis in 1 patient and pulmonary hypertension in another patient. In conclusion, the anti-SS-A antibody is an excellent clue for the early detection of SLE occurring as "idiopathic" thrombocytopenic purpura.
the sole manifestation. In fact, thrombocytopenic purpura is the earliest clinical manifestation in 3% to 16°/o of patients who subsequently develop systemic lupus erythematosus (1) . Furthermore, a positive test for antinuclear antibodies in patients with idiopathic thrombocytopenic purpura often presents diagnostic and therapeutic controversy. Early diagnosis of those with "idiopathic" thrombocytopenic purpura who will ultimately develop systemic lupus erythematosus is important to prevent emergenceof the moreserious manifestations of systemic lupus erythematosus. To diagnose these patients as early as possible, we investigated the early diagnostic clues through a retrospective study of patients with immune thrombocytopenia. Hep-2 cells, a continuous cell line from laryngeal carcinoma. Sera that were positive for FANAwere tested for identification with prototype sera specific for precipitating antibodies to Sm, Ul-RNP, SS-A and SS-B by double immunodiffusion against humanspleen and calf thymus extract. These sera were also tested for antibodies to native DNAby radioimmunoassay (2) . Sera were collected from patients with thrombocytopenia before any therapy was started. Blood was drawn at room temperature. Sera were stored at -70°C until analysis. All patients were followed up at our hospital for at least 5 years. Chi-square analysis with Yates' correction wasused for discrete variables.
PATIENTS AND METHODS

Patien ts
RESULTS
Clinical findings of immune thrombocytopenia
The patients ranged from 15 to 59 years old with a meanof 36 years. There were 30 females and 9 males. Of the 39 patients, 34 (87%) had some manifestations caused by thrombocytopenia including hemorrhagic eruption in 27 (69%), gum bleeding in 10 (26%), epistaxis in 9 (23%), menorrhagia in 7 (1 8%), sustained bleeding after operation in 3 (8%), hematochezia in 2 (5%) and hematuria in 1 (3%). When the initial diagnosis of "idiopathic" thrombocytopenic purpura was made, only these manifestations due to thrombocytopenia were observed ( Table 1) .
Thrombocytopenia of less than 20000/mm3 was found in 21 (54%). Of these 21, ll patients had a more severe form of thrombocytopenia with less than 10000/mm3. Anemia was the next most frequent laboratory finding and was observed in 9 (23%). Anemias were present only to the extent of blood loss. No Coombs-positive hemolytic anemia was observed in association with thrombocytopenia.
Animmunological study disclosed that fluorescent antinuclear antibody was positive in 9 (23%). Amongextractable nuclear antibodies, anti-nRNP Table 2 . Antinuclear antibody in immune thrombocytopenia.
American Rheumatism Association used for the diagnosis of systemic lupus erythematosus from 4.5 to 14 years after the initial diagnosis of "idiopathic" thrombocytopenic purpura. The remaining 5 FANA-positive patients were found to be idiopathic thrombocytopenic purpura after at least a 5-year follow-up.
Characteristics of patients with immunethrombocytopenia which develop SLE
The bleeding manifestations in patients with immune thrombocytopenia who develop SLE tended to be moresevere than in those with idiopathic thrombocytopenic purpura. Profound thrombocytopenia of less than 10000/mm3 was found in 50% of the patients with SLE. On the other hand, it was noted in only 26% of patients with ITP. But the difference between the two groups was not statistically significant.
Amongthe patients with systemic lupus erythematosus who showed "idiopathic" thrombocytopenic purpura at initial presentation, only 4 or 5 findings of diagnostic criteria were observed.
Furthermore, despite the few clinical manifestations, lupus peritonitis was observed in 1 patient, and pulmonary hypertension in 1 (Table 3 ), which are rare in systemic lupus erythematosus. FANA was positive in all patients with systemic lupus erythematosus, and in 5 out of 35 patients with idiopathic thrombocytopenic purpura. The patients with systemic lupus erythematosus did not always have a high titer FANAas shown in Table 2 . None of the four patients had anti-Sm antibody. Of particular interest, all patients who developed systemic lupus were positive for anti-SS-A antibody, in contrast none of the idiopathic thrombocytopenic purpura patients had this antibody.
Clinical characteristics
of FANA-positive ITP Five patients whomwe treated for more than 10 years were proved to be FANApositive idiopathic thrombocytopenic purpura (one patient had a follow-up period of only 5 years). In addition to bleeding manifestations, arthralgia which was seen in 1 patient was the only clinical manifestation noticed during the observation period. Leukopenia was the only abnormal laboratory finding listed in the diagnostic criteria other than positive FANA and thrombocytopenia ( Table 4 ).
The study design and main results are given in 
DISCUSSION
In the evaluation of patients with thrombocytopenia, bone marrowaspiration to evaluate the megakaryocyte count, and a careful review of the patient's medication are mandatory. The patients, in this study, had no drug-related platelet destruction. An increased megakaryocyte counts in the bone marrowwas confirmed in all patients. In addition, at the time of presentation with thrombocytopenia, no clinical manifestations suggestive of systemic The prevalence of thrombocytopenia, as reported in a study of a large series of patients with systemic lupus erythematosus ranges from 14% to 26% (3) . Shortened platelet survival is responsible for the low platelet count in systemic lupus erythematosus and the megakaryocytesin the bone marroware either normal or increased in number. Furthermore, thrombocytopenic purpura is the earliest clinical manifestation in 3% to 16% of patients with systemic lupus erythematosus (3). This makes it important to seek evidence of this disease in all patients with immunethrombocytopenia. Breckenridge and associates suggested that idiopathic thrombocyto-Thrombocytopenia Developing SLE penic purpura and systemic lupus erythematosus can often be distinguished by histological findings of the spleen (4). These criteria are not practical. In addition, Hayes and coworkers reported that no distinguishable pathologic features in the spleen were found in lupus patients after analysis of the splenic pathology of 73 patients with immune thrombocytopenia including 8 patients with systemic lupus erythematosus (5).
Kelton and Gibbons proposed the measurement of antinuclear antibody to rule out systemic lupus erythematosus amongpatients with immunethrombocytopenia (6). However, the presence of autoantibodies to certain defined nuclear antigens is commonly associated with specific rheumatic diseases as well as some immunohematologic diseases including idiopathic thrombocytopenic purpura (7 initial diagnosis of idiopathic thrombocytopenic purpura who developed systemic lupus erythematosus from 1 to 3 years later (7). They emphasized that three of the four of these patients were positive to SS-A. Antibody to an antigen SS-A, which is extractable from a variety of tissues, is found in systemic lupus erythematosus and Sjogren's syndrome (9). Antibody to SS-A antigen has been associated with an increased frequency of photosensitive rash (9). Morley and associates have shown an association between anti-SS-A antibody and the presence of thrombocytopenia; of 32 patients with anti-SS-A antibody, thrombocytopenia occurred in 12 (38%) as compared with 5 out of 32 (16%) patients with systemic lupus erythematosus who lacked the antibody (6). It also frequently occurs in "ANA-negative" systemic lupus erythematosus (1 0). Alger and associates reported a subgroup of patients with systemic lupus erythematosus characterized by thrombocytopenia, hemolytic anemia, and a more benign prognosis (1 1). Anti-SS-A antibody may be a marker of this group. It must be emphasized that the 4 patients in the present study who later developed systemic lupus had only 4 or 5 clinical findings even after fulfilling the diagnostic criteria. The clinical manifestations in these patients were only malar rash and arthritis. Since the diagnosis of idiopathic thrombocytopenic purpura is made by exclusion of other diseases, the differential diagnosis is difficult. Therefore, any clinical marker to predict patients who will ultimately develop systemic lupus would be of considerable value for clinical use. Wepropose that an assay to determine the anti-SS-A antibody should be included in the routine work-up in the evaluation of patients with immunethrombocytopenia. Further, despite the few clinical manifestations, lupus peritonitis was observed in 1 patient and pulmonary hypertension in 1 patient. These have been rare in systemic lupus erythematosus. In conclusion, the antibody to SS-A antibody is an excellent clue for the early detection of patients with
immune thrombocytopenia who will subsequently develop systemic lupus erythematosus.
